Skip to Main Content

Author Details

Giuseppe Curigliano
University of Milan
1996
662
78
PMIDPaper TitleJournal TitlePublished Year
37770765Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.Virchows Arch2024
37669224Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience.Oncologist2024
37715957Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population.Oncologist2024
37548439Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.Oncologist2024
37688414There is no such a thing as a '<i>biological</i>' basis for cancer disparities: A call to end misreporting of the ultimate determinants of health outcomes.Tumori2024
36165912Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.Clin Cancer Res2023
37864956ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.Cancer Treat Rev2023
37528842The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus.EClinicalMedicine2023
37863528Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.ESMO Open2023
37595344Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey.Crit Rev Oncol Hematol2023
37913680Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.Eur J Cancer2023
37665782Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.Oncologist2023
37704501Variant allele frequency: a decision-making tool in precision oncology?Trends Cancer2023
37621172HER2-positive breast cancer: cotargeting to overcome treatment resistance.Curr Opin Oncol2023
37621170Clinical utility of genomic signatures for the management of early and metastatic triple-negative breast cancer.Curr Opin Oncol2023
37621167Immunotherapy for inflammatory breast cancer: current evidences and future perspectives.Curr Opin Oncol2023
37897696Antibody-drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target?Expert Opin Biol Ther2023
37890353Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study.Eur J Cancer2023
37786510Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals.Front Cardiovasc Med2023
37695692A comprehensive update of hormone-related pharmacokinetic variations associated with breast cancer drugs.Expert Opin Drug Metab Toxicol2023
37783318The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility.Crit Rev Oncol Hematol2023
37610519Comment on "Reply: Comment on BIA-ALCL: Comparing the Risk Profiles of Smooth and Textured Breast Implants".Aesthetic Plast Surg2023
37684252Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.NPJ Breast Cancer2023
37683978Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.Ann Oncol2023
37572987ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC).Ann Oncol2023
37499870Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.Ann Oncol2023
37928813News from the San Antonio Breast Cancer Symposium 2022.Breast Care (Basel)2023
37873652Treatment optimization in early triple negative breast cancer.Expert Rev Anticancer Ther2023
37639757Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread.Cancer Treat Rev2023
37291235Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer.NPJ Breast Cancer2023
37022687Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.JAMA Netw Open2023
37455549The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high-volume referral centers.Cancer Med2023
37454444Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study.Eur J Cancer2023
37420274Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study.Mol Cancer Ther2023
36989828Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases.Eur J Cancer2023
37150120Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511].Cancer Treat Rev2023
37451181A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data.Eur J Cancer2023
37343663ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.Ann Oncol2023
37210568Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.Oncologist2023
37210117DESTINY-Breast03 trial: some questions remain - Authors' reply.Lancet2023
37179020Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.Ann Oncol2023
37146504European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care.Eur J Cancer2023
37146385Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?Cancer Treat Rev2023
36980181Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation.Cells2023
37380659Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer.NPJ Breast Cancer2023
37178669Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer.ESMO Open2023
37239021FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma.Biomedicines2023
37467660Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure.ESMO Open2023
37372340Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management.Genes (Basel)2023
37437366Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.Eur J Cancer2023
  • 1 - 50 of 662

Recommended Authors

Amrita Basu
University of California San Francisco
Career Start Year 2018
Number of shared co-authors 3
Padma S Rajagopal
National Cancer Institute, National Institutes of Health
Career Start Year 2014
Number of shared co-authors 4
Chen Hu
Johns Hopkins University School of Medicine
Career Start Year 2009
Number of shared co-authors 6
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 10
Gideon M Blumenthal
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 6
Bora Lim
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 5
Julia A Beaver
Center for Drug Evaluation and Research
Career Start Year 2007
Number of shared co-authors 5
Catherine M Kelly
Mater Misericordiae University Hospital
Career Start Year 2006
Number of shared co-authors 19
Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Career Start Year 2006
Number of shared co-authors 13
Sharon F McGee
The Ottawa Hospital Cancer Centre
Career Start Year 2006
Number of shared co-authors 4
Christina Yau
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 3
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 4
Larissa A Korde
Clinical Investigations Branch, National Cancer Institute
Career Start Year 2004
Number of shared co-authors 26
Matthew P Goetz
Mayo Clinic
Career Start Year 2002
Number of shared co-authors 22
Ingrid A Mayer
Vanderbilt University Medical Center
Career Start Year 2000
Number of shared co-authors 15
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 4
Eleni Andreopoulou
New York Presbyterian Hospital
Career Start Year 1997
Number of shared co-authors 7
Carolien P Schr??der
University of Groningen, University Medical Center Groningen
Career Start Year 1995
Number of shared co-authors 12
Steven J Isakoff
Massachusetts General Hospital
Career Start Year 1995
Number of shared co-authors 10
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 9
Linda T Vahdat
Dartmouth Cancer Center
Career Start Year 1993
Number of shared co-authors 13
Daniel Rea
Institute of Cancer and Genomic Sciences, The University of Birmingham
Career Start Year 1993
Number of shared co-authors 10
Vera J Suman
Mayo Clinic
Career Start Year 1992
Number of shared co-authors 8
Ramona F Swaby
Merck & Co., Inc.
Career Start Year 1991
Number of shared co-authors 3
Caroline Seynaeve
Erasmus Medical Center
Career Start Year 1990
Number of shared co-authors 13
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 17
Luc Dirix
GZA Ziekenhuizen Campus Sint-Augustinus, University of Antwerp
Career Start Year 1988
Number of shared co-authors 29
Stefan Aebi
University of Bern
Career Start Year 1985
Number of shared co-authors 14
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Career Start Year 1984
Number of shared co-authors 8
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 4

Collaborators

Carmen Criscitiello
University of Milano
Co-authored papers 117
Chiara Corti
University of Milano
Co-authored papers 40
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Co-authored papers 28
Sara M Tolaney
Dana-Farber Cancer Institute
Co-authored papers 21
Eric P Winer
Dana-Farber Cancer Institute
Co-authored papers 21
Lisa A Carey
Co-authored papers 20
Nicola Fusco
IEO European Institute of Oncology IRCCS
Co-authored papers 12
Nancy U Lin
Co-authored papers 11
Ian E Krop
Co-authored papers 11
Massimo Cristofanilli
Weill Cornell School of Medicine
Co-authored papers 10
Meredith M Regan
Co-authored papers 10
Alberto Zambelli
IRCCS Humanitas Research Hospital
Co-authored papers 7
Christos Sotiriou
Co-authored papers 7
Isabel T Rubio
Clinica Universidad de Navarra, Cancer Center Universidad de Navarra
Co-authored papers 7
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 7
Jorge S Reis-Filho
Memorial Sloan-Kettering Cancer Center
Co-authored papers 6
William F Symmans
Co-authored papers 6
Clifford A Hudis
Memorial Sloan Kettering Cancer Center, USA American Society of Clinical Oncology
Co-authored papers 6
Larry Norton
Memorial Sloan Kettering Cancer Center
Co-authored papers 6
Lajos Pusztai
Co-authored papers 6
Aditya Bardia
Massachusetts General Hospital Cancer Center
Co-authored papers 5
José Baselga
Co-authored papers 4
Benjamin Solomon
Peter MacCallum Cancer Centre
Co-authored papers 4
Gabriel N Hortobagyi
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Co-authored papers 4
Regina M Santella
Co-authored papers 4
Judy E Garber
Dana-Farber Cancer Institute
Co-authored papers 4
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 4
Kathleen I Pritchard
UCL Great Ormond Street Institute of Child Health, University College London
Co-authored papers 3
Kevin Punie
Leuven Cancer Institute and University Hospitals Leuven
Co-authored papers 3
Release 1.2